Drug – bio-affecting and body treating compositions – Preparations characterized by special physical form – Particulate form
Patent
1995-11-06
1998-07-07
Harrison, Robert H.
Drug, bio-affecting and body treating compositions
Preparations characterized by special physical form
Particulate form
424423, 424451, 424464, 424474, 514937, A61F 202, A61K 914, A61K 920, A61K 948
Patent
active
057764980
ABSTRACT:
A magnesium-taurine compound and its method of synthesis. The compound is synthesized by reacting taurine and magnesium in a 2:1 molar ratio. The resulting mixture is diluted with methanol and the remaining clear filtrate is crystallized from methanol. This compound may be administered orally as a nutritional supplement or may be administered orally or intravenously for treatment of thrombotic or embolic stroke.
REFERENCES:
patent: 4568544 (1986-02-01), Hasegawa et al.
patent: 4857320 (1989-08-01), Wittwer
patent: 4898826 (1990-02-01), Duffy et al.
patent: 5051264 (1991-09-01), Ambrus
patent: 5582839 (1996-12-01), McCarty
T.W. Anderson, et al. (1975) Ischemic heart disease, water hardness and myocardial magnesium. CMA Journal 113:199-203.
S.E. Atahanov, et al. (1992) Modulation of receptor-dependent increase of calcium ions in human platelets by taurine. Arzneim.-Forsch./Drug Res. 42(II):1311-1313.
J. Azuma, et al. (1983) Double-blind randomized crossover trial of taurine in congestive heart failure. Current Therapeutic Res. 34(4):543-557.
T.G. Brott, et al. (1992) Urgent therapy for stroke, Part I. Pilot study of tissue plasminogen activator administered within 90 minutes. Stroke 23:632-640.
B.S. Coller (1990) Platelets and thrombolytic therapy. The New England Journal Of Medicine 322(1):33-42.
T. Dyckner, et al. (1983) Effect of magnesium on blood pressure. British Medical Journal 286:1847-1849.
H.J. Gelmers, et al. (1988) A controlled trial of nimodipine in acute ischemic stroke. The New England Journal of Medicine 318(4):203-207.
W. Hacke, et al. (1988) Intra-arterial thrombolytic therapy improves outcome in patients with acute vertebrobasilar occlusive disease. Stroke 19(10):1216-1222.
K.C. Hayes, et al. (1989) Taurine modulates platelet aggregation in cats and human. Am. J. Clin. Nutr. 49:1211-1216.
R.J. Huxtable (1992) Physiological actions of taurine. Physiological Reviews 72(1):101-163.
L.T. Iseri (1984) Magnesium in coronary artery disease. Drugs 28(Suppl. 1):151-160.
M. Malcangio, et al. (1989) Effect of ICV taurine on the impairment of learning, convulsions and death caused by hypoxia. Psychopharmacology 98:316-320.
T. Motoyama, et al. (1989) Oral magnesium supplementation in patients with essential hypertension. Hypertension 13:227-232.
A. Puca (1993) Thrombolysis in cerebral ischemia. A review of clinical and experimental data. Journal Neurosurg. Science 37:63-70.
S.M. Rothman (1983) Synaptic activity mediates death of hypoxic neurons. Science 220:536-537.
M.P. Ryan, et al. (1984) The role of magnesium in the prevention and control of hypertension. Ann. Clin. Res. 16:82-88.
S.W. Schaffer, et al. (1990) Regulation of calcium homeostasis by taurine: role of calmodulin. Taurine: Functional Neurochemistry, Physiology, and Cardiology 217-225.
S.W. Schaffer, et al. (1994) Mechanisms underlying physiological and pharmacological actions of taurine on myocardial calcium transport. Taurine in Health and Disease 171-180.
A. Schurr, et al. (1987) Taurine improves the recovery of neuronal function following cerebral hypoxia: an in vitro study. Life Sciences 40:2059-2066.
M.S. Seelig, et al. (1974) Magnesium interrelationships in ishemic heart disease: a review. The American Journal of Clinical Nutrition 27: 59-79.
M. Shechter, et al. (1992) The rationale of magnesium supplementation in acute myocardial infarction Arch Intern. Med. 152:2189-2196.
Trust Study Group (1990) Randomised, double-blind, placebo-controlled trial of nimodipine in acute stroke. The Lancet 336:1205-1209.
B.C. White, et al. (1984) Brain ischemic anoxia. JAMA 251(12):1586-1590.
M.C.W. Wong, et al. (1990) Calcium antagonists: stroke therapy coming of age. Stroke 21(3):494-501.
Harrison Robert H.
Nutrition 21
LandOfFree
Magnesium taurate as an adjuvant to rapid thrombolytic therapy does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Magnesium taurate as an adjuvant to rapid thrombolytic therapy, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Magnesium taurate as an adjuvant to rapid thrombolytic therapy will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1202796